glp 1 nature GLP-1-based therapies for diabetes, obesity and beyond ISO 17025 Lab Tested GLP-1 Genetics: How Genes Affect

Glutathione and infection // Biochimica et Biophysica Acta

Amylyx Pharmaceuticals announced Wednesday it has acquired a glucagon-like peptide-1 receptor antagonist, avexitide, from Eiger BioPharmaceuticals that is ready for Phase III trials and has been granted FDA Breakthrough Therapy Designation for post-bariatric hypoglycemia and congenital hyperinsulinism

10.2147/DMSOTT.S7327 4 AlbiE.CataldiS.LazzariniA.CodiniM.BeccariT.Ambesi-ImpiombatoF

Additionally, a polymeric CXCR4 antagonist (PCX) complexed with p53 siRNA (PCX/sip53) combines gene silencing with CXCR4 blockade, achieving simultaneous inhibition of apoptosis and inflammatory cell recruitment in cisplatin and bilateral IRI models while avoiding hepatic and splenic clearance due to its optimized nanoscale size [102]

Definitely worth it

Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist